Show simple item record

dc.contributor.authorSestak, Joshua
dc.contributor.authorSullivan, Bradley P.
dc.contributor.authorThati, Shara
dc.contributor.authorNorthrup, Laura Ann
dc.contributor.authorHartwell, Brittany
dc.contributor.authorAntunez, Lorena
dc.contributor.authorForrest, M. Laird
dc.contributor.authorVines, Charlotte M.
dc.contributor.authorSiahaan, Teruna J.
dc.contributor.authorBerkland, Cory J.
dc.identifier.citationSestak, Joshua O., Bradley P. Sullivan, Sharadvi Thati, Laura Northrup, Brittany Hartwell, Lorena Antunez, M. Laird Forrest, Charlotte M. Vines, Teruna J. Siahaan, and Cory Berkland. "Codelivery of Antigen and an Immune Cell Adhesion Inhibitor Is Necessary for Efficacy of Soluble Antigen Arrays in Experimental Autoimmune Encephalomyelitis." Molecular Therapy — Methods & Clinical Development Mol Ther Methods Clin Dev 1 (2014): 14008. doi: 10.1038/mtm.2014.8.en_US
dc.descriptionThis is the published version. Copyright 2014 Nature Publishing Group.en_US
dc.description.abstractAutoimmune diseases such as multiple sclerosis (MS) are typified by the misrecognition of self-antigen and the clonal expansion of autoreactive T cells. Antigen-specific immunotherapies (antigen-SITs) have long been explored as a means to desensitize patients to offending self-antigen(s) with the potential to retolerize the immune response. Soluble antigen arrays (SAgAs) are composed of hyaluronic acid (HA) cografted with disease-specific autoantigen (proteolipid protein peptide) and an ICAM-1 inhibitor peptide (LABL). SAgAs were designed as an antigen-SIT that codeliver peptides to suppress experimental autoimmune encephalomyelitis (EAE), a murine model of MS. Codelivery of antigen and cell adhesion inhibitor (LABL) conjugated to HA was essential for SAgA treatment of EAE. Individual SAgA components or mixtures thereof reduced proinflammatory cytokines in cultured splenocytes from EAE mice; however, these treatments showed minimal to no in vivo therapeutic effect in EAE mice. Thus, carriers that codeliver antigen and a secondary “context” signal (e.g., LABL) in vivo may be an important design criteria to consider when designing antigen-SIT for autoimmune therapy.en_US
dc.publisherNature Publishing Groupen_US
dc.titleCodelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitisen_US
kusw.kuauthorSestak, Joshua O.
kusw.kuauthorSullivan, Bradley Paul
kusw.kuauthorForrest, M. Laird
kusw.kuauthorSiahaan, Teruna J.
kusw.kuauthorBerkland, Cory J.
kusw.kudepartmentPharmaceutical Chemistryen_US
kusw.oanotesAuthor's Pre-print: green tick author can archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: green tick author can archive publisher's version/PDF General Conditions:

Authors retain copyright Published source must be acknowledged and DOI cited Must link to publisher version Publisher's version/PDF may be used On open access repositories Creative Commons Attribution License, Creative Commons Attribution Non-Commercial Share Alike License or Creative Commons Attribution Non-Commercial No-Derivatives License
kusw.oaversionScholarly/refereed, publisher version
kusw.oapolicyThis item meets KU Open Access policy criteria.

Files in this item


This item appears in the following Collection(s)

Show simple item record